Hepatitis C in Argentina: epidemiology and treatment

Luis Alejandro Gaite, Sebastián Marciano, Omar Andrés Galdame, Adrián Carlos GadanoHepatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gaite LA, Marciano S, Galdame OA, Gadano AC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/625cdf132bc54934940b49a496d92edf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:625cdf132bc54934940b49a496d92edf
record_format	dspace
spelling	oai:doaj.org-article:625cdf132bc54934940b49a496d92edf2021-12-02T00:21:02ZHepatitis C in Argentina: epidemiology and treatment1179-1535https://doaj.org/article/625cdf132bc54934940b49a496d92edf2014-05-01T00:00:00Zhttp://www.dovepress.com/nbsphepatitis-c-in-argentina-epidemiology-and-treatment-a17008https://doaj.org/toc/1179-1535 Luis Alejandro Gaite, Sebastián Marciano, Omar Andrés Galdame, Adrián Carlos GadanoHepatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, where from 1.5% to 2.5% of adults are infected. Most of the infections were acquired 30–50 years ago. It is estimated that more than half of infected individuals are not aware of their infection. Even though the prevalence in blood donors has decreased to 0.45% at present, many high-prevalence populations still exist, where the reported prevalence ranges from 2.2% to 7.1%. Therapy is recommended for patients with fibrosis, in order to prevent disease progression, hepatic decompensation, and hepatocellular carcinoma. Great advances were achieved in the treatment of genotype 1 infection since the development and release of boceprevir and telaprevir. When either of these protease inhibitors is associated with peginterferon plus ribavirin, the sustained virological response (SVR) rate improves from 40%–50% to 67%–75%. For genotype 2 and 3 infection, treatment with peginterferon plus ribavirin is still the standard of care, with SVR rates of 70%–90%. There are significant new antivirals in development, and some of them are close to being released. These drugs will most likely be the future standard of care for all genotypes, and will be incorporated in better-tolerated and highly effective all-oral regimes. The impact that these new therapies might have in health-related economics is unpredictable, especially in developing countries. Each country must carefully evaluate the local situation in order to implement proper screening and treatment programs. Difficult-to-treat patients, such as those with decompensated cirrhosis, patients in hemodialysis, and those with other significant comorbidities, might not be able to receive these new therapeutic approaches and their management will remain challenging.Keywords: hepatitis C, prevalence, transmission, therapeutics, genotype, Latin AmericaGaite LAMarciano SGaldame OAGadano ACDove Medical PressarticleDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2014, Iss default, Pp 35-43 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 Gaite LA Marciano S Galdame OA Gadano AC Hepatitis C in Argentina: epidemiology and treatment
description	Luis Alejandro Gaite, Sebastián Marciano, Omar Andrés Galdame, Adrián Carlos GadanoHepatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, ArgentinaAbstract: Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, and liver cancer in Argentina, where from 1.5% to 2.5% of adults are infected. Most of the infections were acquired 30–50 years ago. It is estimated that more than half of infected individuals are not aware of their infection. Even though the prevalence in blood donors has decreased to 0.45% at present, many high-prevalence populations still exist, where the reported prevalence ranges from 2.2% to 7.1%. Therapy is recommended for patients with fibrosis, in order to prevent disease progression, hepatic decompensation, and hepatocellular carcinoma. Great advances were achieved in the treatment of genotype 1 infection since the development and release of boceprevir and telaprevir. When either of these protease inhibitors is associated with peginterferon plus ribavirin, the sustained virological response (SVR) rate improves from 40%–50% to 67%–75%. For genotype 2 and 3 infection, treatment with peginterferon plus ribavirin is still the standard of care, with SVR rates of 70%–90%. There are significant new antivirals in development, and some of them are close to being released. These drugs will most likely be the future standard of care for all genotypes, and will be incorporated in better-tolerated and highly effective all-oral regimes. The impact that these new therapies might have in health-related economics is unpredictable, especially in developing countries. Each country must carefully evaluate the local situation in order to implement proper screening and treatment programs. Difficult-to-treat patients, such as those with decompensated cirrhosis, patients in hemodialysis, and those with other significant comorbidities, might not be able to receive these new therapeutic approaches and their management will remain challenging.Keywords: hepatitis C, prevalence, transmission, therapeutics, genotype, Latin America
format	article
author	Gaite LA Marciano S Galdame OA Gadano AC
author_facet	Gaite LA Marciano S Galdame OA Gadano AC
author_sort	Gaite LA
title	Hepatitis C in Argentina: epidemiology and treatment
title_short	Hepatitis C in Argentina: epidemiology and treatment
title_full	Hepatitis C in Argentina: epidemiology and treatment
title_fullStr	Hepatitis C in Argentina: epidemiology and treatment
title_full_unstemmed	Hepatitis C in Argentina: epidemiology and treatment
title_sort	hepatitis c in argentina: epidemiology and treatment
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/625cdf132bc54934940b49a496d92edf
work_keys_str_mv	AT gaitela hepatitiscinargentinaepidemiologyandtreatment AT marcianos hepatitiscinargentinaepidemiologyandtreatment AT galdameoa hepatitiscinargentinaepidemiologyandtreatment AT gadanoac hepatitiscinargentinaepidemiologyandtreatment
_version_	1718403803240202240

Hepatitis C in Argentina: epidemiology and treatment

Ejemplares similares